REGENXBIO INC. DL-,0001 WKN: A140E0 ISIN: US75901B1070 Kürzel: RB0 Forum: Aktien Thema: Hauptdiskussion

https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-pivotal-trial-rgx-121-treatment-mps-ii

https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-completion-enrollment-cohort-2-and

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society https://www.prnewswire.com/news-releases/regenxbio-presents-interim-clinical-data-from-phase-iii-affinity-duchenne-trial-of-rgx-202-at-28th-annual-international-congress-of-the-world-muscle-society-301946289.html

https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2023-financial-results-and-recent-operational-highlights-301891935.html

https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-reports-first-quarter-2023-financial-results-and

https://www.prnewswire.com/news-releases/regenxbio-receives-fda-fast-track-designation-for-rgx-202-a-novel-gene-therapy-candidate-for-the-treatment-of-duchenne-muscular-dystrophy-301794029.html

🎈

https://www.prnewswire.com/news-releases/regenxbio-reports-fourth-quarter-2022-and-full-year-2022-financial-results-and-recent-operational-highlights-301758593.html

https://www.prnewswire.com/news-releases/additional-positive-interim-data-from-phase-iiiiii-campsiite-trial-of-regenxbios-rgx-121-for-the-treatment-of-mps-ii-hunter-syndrome-presented-at-19th-annual-worldsymposiumtm-301753564.html

https://www.prnewswire.com/news-releases/regenxbio-presents-interim-data-from-phase-ii-bridging-study-evaluating-the-clinical-performance-of-rgx-314-using-the-navxpress-manufacturing-platform-process-301744570.html

https://www.prnewswire.com/news-releases/regenxbio-announces-phase-iii-trial-of-rgx-202-a-novel-gene-therapy-candidate-for-duchenne-muscular-dystrophy-is-active-and-recruiting-patients-301727802.html

https://www.prnewswire.com/news-releases/regenxbio-reports-update-on-advancement-of-programs-for-cln2-disease-301707881.html

https://www.prnewswire.com/news-releases/regenxbio-announces-completion-of-dosing-in-the-phase-iii-trial-of-rgx-111-for-the-treatment-of-severe-mps-i-301697997.html

👀

https://finance.yahoo.com/news/regenxbio-rgnx-reports-q3-loss-124512911.html

https://www.prnewswire.com/news-releases/regenxbio-reports-third-quarter-2022-financial-results-and-recent-operational-highlights-301667151.html